Gout, an inflammatory arthritis resulting from monosodium urate (MSU) crystal deposition, is traditionally managed by lowering serum urate (SU) to dissolve crystals and prevent flares.1 Current guidelines recommend a treat-to-target (T2T) strategy, targeting SU < 360 µmol/L (6 mg/dL)—or <300 µmol/L (5 mg/dL) for severe tophaceous gout2—to avoid hyperuricemia-related long-term complications. Yet sole SU focus has limits: many patients still have acute flares or slow tophus resolution despite reaching the target. For example, in a T2T cohort, only 5% achieved comprehensive remission after 1 year of urate-lowering therapy (ULT), compared with over 40% at 5 years, indicating protracted crystal clearance despite stable SU control.3 This gap underscores gout is not just defined by SU; persistent inflammation and residual crystal burden are additional disease activity dimensions not fully captured by SU alone. To achieve true “cure” in gout, emerging evidence supports a phased approach targeting its two key biological phases: innate immune-mediated acute inflammation and metabolic dysregulation-driven chronic crystal deposition. This report analyzes the scientific rationale, clinical evidence, and implementation of a “Two-Stage T2T Strategy,” consisting of an initial “Metabolic and Immune Control” stage and a subsequent “Biochemical and Structural Remission” stage. It seeks to offer an evidence-based roadmap, confirming the need to go beyond pure urate control to verifiable structural remission and define a clinical “cure” pathway for gout. Gout's pathophysiology is encapsulated by the “seed and soil” analogy: hyperuricemia (the “seed”) facilitates MSU crystal formation and growth, while the inflammatory milieu (NLRP3 inflammasome activation, the “soil”) determines if crystals stay inert or trigger acute flares. Standard T2T strategies fall short by targeting only the “seed” (urate) and ignoring the “soil's” (inflammation) early dynamic reactivity. ULT initiation paradoxically destabilizes crystals, releasing them into the synovial space; macrophage phagocytosis triggers interleukin (IL)-1β and “mobilization flares”—the leading cause of treatment dropout.4 Thus, a two-stage strategy prioritizing immune stabilization with metabolic control in Stage 1 is no mere semantic distinction from guidelines, but a critical operational advancement to retain patients for Stage 2. Unlike rheumatoid arthritis (RA), where “remission” suppresses autoimmunity without reversing structural damage, gout is uniquely a potentially curable rheumatic disease—its pathogenic MSU crystals are reversible and fully dissolvable with sustained subsaturating urate levels. Yet gout's “cure” or “complete remission” definition is controversial: is biochemical normouricemia enough, or is physical crystal burden elimination necessary? Longitudinal dual-energy computed tomography (DECT) studies show substantial crystals may persist in tendons and deep tissues for years despite SU target achievement.5 This “silent” burden triggers chronic subclinical inflammation, progressive joint erosion, and cardiovascular risk. Thus, this report advocates imaging-verified “Structural Remission” as gout's ultimate therapeutic endpoint, distinct from symptom-free “Clinical Remission” endorsed in standard practice. The primary objective of Stage 1 of the proposed Two-Stage Strategy is stabilization, encompassing ULT initiation and the critical initial 6–12 months of therapy—a period marked by high flare risk and attrition rates. All major guidelines endorse SU lowering: ACR 2020 strongly recommends a <6 mg/dL target for all ULT patients,1 while EULAR aligns and advises a <5 mg/dL (<300 µmol/L) target for severe gout to speed crystal dissolution.2 The Two-Stage Strategy upholds these targets but stresses SU reduction kinetics, as rapid lowering raises flare risk. Thus, Stage 1 protocols balance urate-lowering urgency with destabilization risk, employing “start low, go slow” titration for allopurinol and febuxostat—especially for Asian populations or those with renal impairment, who face elevated hypersensitivity risks.6 In Stage 1, inflammation management is as critical as SU reduction7; the “Immune Target” suppresses the NLRP3-IL-1β axis to prevent flares and boost adherence. IL-1β is the key gout inflammatory cytokine: MSU crystal phagocytosis triggers NLRP3 inflammasome assembly, caspase-1 activation, and pro-IL-1β cleavage, recruiting neutrophils and driving flares. The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial confirmed IL-1β's role: canakinumab (anti-IL-1β monoclonal antibody) reduced gout flares by over 50% regardless of baseline urate, without changing SU,7 proving inflammation (“soil”) can be treated independently of urate (“seed”). Guidelines categorize IL-1 inhibitors as second-line/conditional but acknowledge their superiority in specific cases. For chronic kidney disease Stage 3+ patients (a large gout subset), NSAIDs are often contraindicated, and colchicine needs cautious dosing; IL-1 inhibitors may be the only safe option for flare control during ULT initiation.8 Thus, the Two-Stage Strategy's “Immune Control” frames IL-1 inhibitors not as an option, but a necessity for complex patients to finish Stage 1 without treatment dropout. Successful Stage 1 completion is defined by achieving the SU target (<6 mg/dL) and flare cessation (clinical remission), creating a “dissolution-friendly” state. But per the NOR-Gout study, patients here likely still have substantial crystal loads—clinically silent yet structurally active. Recognizing this distinction is the Two-Stage Strategy's key innovation, transitioning patients from “stabilized” to “in remission.” With short-term gout control achieved, focus shifts to eradicating crystal burden for durable remission. Stage 2 objectives: (1) Biochemical: sustain SU targets, with individualized intensification to <5 mg/dL for heavy crystal loads to accelerate dissolution9; (2) Structural: eliminate MSU deposits (confirmed via exam/imaging). Advanced imaging (DECT,10 ultrasound) enables objective monitoring to confirm structural remission. Sustained ULT and inflammation control drives gradual crystal reduction. The NOR-Gout study showed target ULT led to marked MSU deposit reduction over years, with tophus-free rates rising from ~5% at 1 year to ~95% at 5 years,3 highlighting the need for prolonged therapy. Guidelines recommend 6 months of prophylaxis, but high tophus burden may require longer; periodic imaging guides decisions—persistent crystals prompt continued treatment, while crystal absence justifies tapering and remission declaration. Crucially, structural remission verification is Stage 2's endpoint—symptom improvement alone is inadequate; pathogenic urate pools must be confirmed eliminated. A DECT study linked remission (no flares, low pain, SU < 6 mg/dL for 12 months) to minimal residual urate, while non-remission patients had substantial crystals,11 confirming true remission correlates with crystal clearance. Eliminating deposits addresses joint damage's root cause, halting erosion and enabling partial healing to prevent future arthritis and disability. Practically, annual DECT/ultrasound quantifies crystals in longstanding/tophaceous gout,12 boosting adherence via visible progress. Monitoring SU and crystal dissolution (e.g., DECT-depicted reduction) improves long-term ULT adherence.13, 14 Stage 2 ends with sustained target SU and imaging/clinical confirmation of crystal clearance, aligning with 2016 Delphi criteria: SU < 6 mg/dL, no flares or tophi, minimal pain for ≥12 months,4, 15 maximizing future gout risk reduction. Gout management requires an integrated sequential pathway, not viewing dual goals as mutually exclusive. It comprises two continuous, interdependent stages: Stage 1 (Process-Oriented): Primary goal is metabolic and immune stability, achieved via strict ULT plus anti-inflammatory prophylaxis (e.g., colchicine) to sustain low SU and prevent flares, laying the groundwork for long-term therapy. Stage 2 (Outcome-Oriented): Primary goal is verifying and achieving remission. Building on stability, it focuses on monitoring/eliminating urate crystals (e.g., via imaging) to eradicate the disease's pathological basis and attain true cure (Figure 1). Practically, the stages connect seamlessly and may overlap. For example, after 6–12 months of successful ULT, imaging initiates crystal clearance monitoring (early Stage 2) while prophylaxis continues. Prophylaxis is safely discontinued only when imaging confirms major crystal burden elimination—by Stage 2's end, flares are unlikely as their crystal “fuel” is largely gone. Patient education is critical: they must understand the goal is curing the disease (not just relieving pain), requiring prolonged therapy postsymptom resolution. This two-phase T2T approach provides a clear roadmap from short-term control to long-term remission. Multi-dimensional staged gout targets mark a shift toward cure-focused care. Prospective trials are required to validate the two-stage T2T strategy's superiority over conventional management, addressing key questions: optimal Stage 1 prophylaxis duration (e.g., IL-1 inhibitors/extended colchicine for high-risk patients until crystal dissolution), ideal Stage 2 monitoring tools/intervals (ultrasound vs. DECT for routine clearance), phase-specific biomarkers (IL-1, imaging scores), and personalized pathways tailored to tophus burden, comorbidities, and flare frequency. Groundwork for this paradigm shift is already laid: gout remission is no longer vague but achievable with proper management, supported by multi-domain (clinical, biochemical, imaging) criteria and long-term studies showing sustained ULT eliminates flares/tophi in most patients, improving quality of life and halting joint damage. Following RA's T2T revolution, gout is poised to emulate this success—with the unique potential for “cure” via complete crystal eradication. In conclusion, gout management enters an era of multi-target, phase-based therapy aimed at complete remission. Integrating “metabolic+immune” and “biochemical+structural” frameworks, the two-stage strategy (first stabilizing inflammation/urate, then clearing crystals) transforms gout from chronic-relapsing to conquerable. Clinicians must expand focus beyond SU to inflammation control and crystal burden assessment. This approach aligns treatment with its ultimate goal: true remission. The paradigm shifts from managing to curing gout, with the two-stage T2T strategy as the enabler. It is important to note that the clinical application of DECT requires consideration of its associated costs. We therefore suggest that DECT be employed primarily as a precise diagnostic tool for complex cases where clinical diagnosis is ambiguous, or where conventional imaging yields inconclusive results, rather than as a routine screening tool for all patients. This approach ensures optimal allocation of healthcare resources. Jiani Liu: Conceptualization; investigation; formal analysis; writing—original draft. Ziwen Xu: Data curation; writing—review and editing; investigation. Wenxi Cui: Formal analysis; visualization; investigation. Man Lu: Investigation; data curation; methodology. Qingqing Zhang: Writing—review and editing; project administration; investigation. Wenxia Lin: Investigation; writing—review and editing. Shixian Chen: Project administration; formal analysis; writing—review and editing. Weikai Lin: Investigation; data curation; project administration. Guichuan Lai: Funding acquisition; supervision; project administration. Juan Li: Writing— review and editing; supervision; project administration. Meng Li: Methodology; supervision; project administration. This work was supported by grants from the Guangzhou Traditional Chinese Medicine major science and technology project (Nos. 2025CX003, 2025QN003), and the China Postdoctoral Science Foundation (No. 2025M782045). The authors declare no conflicts of interest. The authors have nothing to report. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Liu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: